Supernus Pharmaceuticals Analyst Ratings
Supernus Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 65.9% | Piper Sandler | $42 → $43 | Maintains | Overweight |
| 10/25/2023 | 62.04% | Piper Sandler | $43 → $42 | Maintains | Overweight |
| 05/10/2023 | 77.47% | Piper Sandler | $45 → $46 | Maintains | Overweight |
| 01/23/2023 | 81.33% | Piper Sandler | $40 → $47 | Maintains | Overweight |
| 08/31/2022 | 46.6% | Piper Sandler | $33 → $38 | Maintains | Overweight |
| 04/13/2021 | 54.32% | Jefferies | $25 → $40 | Upgrades | Hold → Buy |
| 06/16/2020 | 19.6% | Piper Sandler | $25 → $31 | Upgrades | Neutral → Overweight |
| 06/15/2020 | -7.41% | Jefferies | → $24 | Reinstates | → Hold |
| 04/16/2020 | -7.41% | Stifel | $25 → $24 | Maintains | Hold |
| 11/07/2019 | -11.27% | Stifel | $55 → $23 | Downgrades | Buy → Hold |
| 11/06/2019 | — | Jefferies | Downgrades | Buy → Hold | |
| 12/17/2018 | 143.06% | Mizuho | $61 → $63 | Maintains | Buy |
| 11/12/2018 | 150.77% | B. Riley Securities | $68 → $65 | Maintains | Buy |
| 日期 | 上行/下行 | 分析师事务所 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/09/2023 | 65.9% | 派珀·桑德勒 | 42 美元 → 43 美元 | 维护 | 超重 |
| 2023 年 10 月 25 日 | 62.04% | 派珀·桑德勒 | 43 美元 → 42 美元 | 维护 | 超重 |
| 05/10/2023 | 77.47% | 派珀·桑德勒 | 45 美元 → 46 美元 | 维护 | 超重 |
| 2023 年 1 月 23 日 | 81.33% | 派珀·桑德勒 | 40 美元 → 47 美元 | 维护 | 超重 |
| 08/31/2022 | 46.6% | 派珀·桑德勒 | 33 美元 → 38 美元 | 维护 | 超重 |
| 04/13/2021 | 54.32% | 杰富瑞集团 | 25 美元 → 40 美元 | 升级 | 持有 → 买入 |
| 06/16/2020 | 19.6% | 派珀·桑德勒 | 25 美元 → 31 美元 | 升级 | 中性 → 增持 |
| 06/15/2020 | -7.41% | 杰富瑞集团 | → 24 美元 | 恢复 | → 按住 |
| 2020 年 4 月 16 日 | -7.41% | Stifel | 25 美元 → 24 美元 | 维护 | 保持 |
| 11/07/2019 | -11.27% | Stifel | 55 美元 → 23 美元 | 降级 | 买入 → 持有 |
| 11/06/2019 | — | 杰富瑞集团 | 降级 | 买入 → 持有 | |
| 12/17/2018 | 143.06% | 瑞穗市 | 61 美元 → 63 美元 | 维护 | 购买 |
| 11/12/2018 | 150.77% | B. 莱利证券 | 68 美元 → 65 美元 | 维护 | 购买 |
What is the target price for Supernus Pharmaceuticals (SUPN)?
Supernus Pharmicals（SUPN）的目标价格是多少？
The latest price target for Supernus Pharmaceuticals (NASDAQ: SUPN) was reported by Piper Sandler on November 9, 2023. The analyst firm set a price target for $43.00 expecting SUPN to rise to within 12 months (a possible 65.90% upside). 4 analyst firms have reported ratings in the last year.
派珀·桑德勒于2023年11月9日公布了Supernus Pharmicals（纳斯达克股票代码：SUPN）的最新目标股价。该分析公司将目标股价定为43.00美元，预计SUPN将在12个月内上涨至43.00美元（可能上涨65.90％）。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Supernus Pharmaceuticals (SUPN)?
Supernus Pharmicals（SUPN）的最新分析师评级是多少？
The latest analyst rating for Supernus Pharmaceuticals (NASDAQ: SUPN) was provided by Piper Sandler, and Supernus Pharmaceuticals maintained their overweight rating.
Supernus Pharmicals（纳斯达克股票代码：SUPN）的最新分析师评级由派珀·桑德勒提供，Supernus Pharmicals维持其增持评级。
When is the next analyst rating going to be posted or updated for Supernus Pharmaceuticals (SUPN)?
Supernus Pharmicals（SUPN）的下一个分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Supernus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Supernus Pharmaceuticals was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Supernus Pharmicals的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Supernus Pharmicals的最新评级是在2023年11月9日提交的，因此您应该预计下一个评级将在2024年11月9日左右公布。
Is the Analyst Rating Supernus Pharmaceuticals (SUPN) correct?
分析师评级Supernus Pharmicals（SUPN）是否正确？
While ratings are subjective and will change, the latest Supernus Pharmaceuticals (SUPN) rating was a maintained with a price target of $42.00 to $43.00. The current price Supernus Pharmaceuticals (SUPN) is trading at is $25.92, which is out of the analyst's predicted range.
尽管评级是主观的，并将发生变化，但Supernus Pharmicals（SUPN）的最新评级维持不变，目标股价为42.00美元至43.00美元。Supernus Pharmicals（SUPN）目前的交易价格为25.92美元，超出了分析师的预期区间。